ResMed (NYSE: RMD) announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments Momentum Movers

Jefferies Drops Price Target After ResMed (RMD) Heart Failure Trial Fails May 14, 2015 10:19 AM BofA/Merrill Lynch Downgrades ResMed (RMD) to NeutralMay 13, 2015 8:44 AM Form 8-K RESMED INC For: May 13May 13, 2015 6:09 AM ResMed Provides Update on Phase III SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy In Central Sleep Apnea and Chronic Heart FailureMay 13, 2015 3:00 AM